US Court Denies Teva's Motion for Summary Judgment in PULMICORT RESPULES(R) Patent Litigation

WILMINGTON, Del., Sept. 23  /PRNewswire-FirstCall/ -- AstraZeneca today announced that the US District Court for the District of New Jersey has denied Teva's Motion for Summary Judgment of no infringement in the PULMICORT RESPULES(R) (budesonide inhalation suspension) patent litigation.

The court also announced that a trial date will be scheduled and is likely to be in January of 2009. AstraZeneca remains focused on preparing for this trial and is confident in the strength of the intellectual property protecting PULMICORT RESPULES.

In October of 2005, AstraZeneca announced that it had filed a lawsuit in the US District Court for the District of New Jersey against IVAX Pharmaceuticals, Inc. (now known as Teva Pharmaceutical Industries Ltd.) for patent infringement.  The lawsuit is the result of an abbreviated New Drug Application (ANDA) filed by Teva with the US Food and Drug Administration (FDA) concerning its intent to market a generic version of AstraZeneca's PULMICORT RESPULES in the US prior to the expiration of AstraZeneca's patents in 2018, with pediatric exclusivity extending to 2019.

The FDA has not approved a generic form of PULMICORT RESPULES, and has not yet responded to AstraZeneca's Citizen Petition, filed in 2006. The Petition outlined AstraZeneca's willingness to work with the FDA to ensure that any follow-on budesonide inhalation suspension product is as safe and effective as PULMICORT RESPULES.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. 

DATASOURCE: AstraZeneca



CONTACT:  Media Enquiries UK, Neil McCrae, [phone] (24 hours),

or Chris Sampson, [phone] (24 hours); Media Enquiries US, Emily

Denney, [phone]; Investor Enquiries UK, Jonathan Hunt, [phone]

5087, Cell, [phone], Mina Blair, [phone], Cell, +44 7718

581021, or Karl Hard, [phone], Cell, [phone]; Investor

Enquiries US, Ed Seage, [phone], Cell, [phone], Jorgen

Winroth, [phone], Cell, [phone], or Peter Vozzo (MedImmune),

[phone], Cell, [phone]



Web site:  http://www.astrazeneca-us.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/985887.html 

Copyright